Compugen Ltd.(CGEN)

Description: Compugen Ltd., a therapeutic product discovery company, engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates primarily in the United States, Europe, and Israel. It focuses on the therapeutic proteins and monoclonal antibodies to address unmet needs in the fields of immunology and oncology. The company's therapeutic proteins pipeline includes CGEN-15001, a novel protein for the treatment of autoimmune disorders; CGEN-15021, a novel fusion protein for the treatment of multiple sclerosis, rheumatoid arthritis, and other autoimmune diseases; CGEN-15091, a novel fusion protein for the treatment of multiple sclerosis and autoimmune diseases; CGEN-15031, a fusion protein candidate to treat multiple sclerosis; and CGEN-15051, a fusion protein candidate for the treatment of rheumatoid arthritis. Its monoclonal antibody therapy product candidates include CGEN-15001T, a membrane protein target for the treatment of cancer; CGEN-15022 membrane protein for the treatment of multiple cancers; CGEN-671, a novel drug target for the treatment of multiple epithelial tumors; and CGEN-928 drug target for the treatment of multiple myeloma. Compugen Ltd. was founded in 1993 and is headquartered in Tel Aviv, Israel.

---

Keywords: Medicine Cancer Biopharmaceutical Life Sciences Immunology Antibodies Treatment Of Cancer Autoimmune Disease Monoclonal Antibodies Rheumatoid Arthritis Antibody Monoclonal Antibody Biomarkers Multiple Sclerosis Therapeutic Products Multiple Myeloma Autoimmunity Monoclonal Antibody Therapy Autoimmune Disorders Immune Disorders Compugen Fusion Protein Treatment Of Multiple Sclerosis Antibody Therapy

---

Home Page: cgen.com

CGEN Technical Analysis

Azrieli Center
Holon, 5885849
Israel
Phone: 972 3 765 8585

---

Officers

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)